These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 38319153)

  • 1. Efficacy and Safety of AbobotulinumtoxinA for Treatment of Moderate-to-Severe Glabellar Lines: A Meta-Analysis.
    Han X; Bai J; Kuang J
    Ophthalmic Plast Reconstr Surg; 2024 Mar-Apr 01; 40(2):126-133. PubMed ID: 38319153
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and Safety of AbobotulinumtoxinA for the Treatment of Glabellar Lines in Chinese Patients: A Pivotal, Phase 3, Randomized, Double-Blind and Open-Label Phase Study.
    Wu Y; Fang F; Lai W; Li C; Li L; Liu Q; Lu J; Pang X; Sun J; Shi X; Picaut P; Prygova I; Andriopoulos B; Sun Q
    Aesthetic Plast Surg; 2023 Feb; 47(1):351-364. PubMed ID: 36536093
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Liquid Formulation of AbobotulinumtoxinA Exhibits a Favorable Efficacy and Safety Profile in Moderate to Severe Glabellar Lines: A Randomized, Double-Blind, Placebo- and Active Comparator-Controlled Trial.
    Ascher B; Kestemont P; Boineau D; Bodokh I; Stein A; Heckmann M; Dendorfer M; Pavicic T; Volteau M; Tse A; Picaut P; Rzany B
    Aesthet Surg J; 2018 Feb; 38(2):183-191. PubMed ID: 28200002
    [TBL] [Abstract][Full Text] [Related]  

  • 4. An analysis of efficacy data from four phase III studies of botulinum neurotoxin type A-ABO for the treatment of glabellar lines.
    Baumann L; Brandt FS; Kane MA; Donofrio LM
    Aesthet Surg J; 2009 Nov; 29(6 Suppl):S57-65. PubMed ID: 19945006
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Liquid Formulation of AbobotulinumtoxinA: A 6-Month, Phase 3, Double-Blind, Randomized, Placebo-Controlled Study of a Single Treatment, Ready-to-Use Toxin for Moderate-to-Severe Glabellar Lines.
    Ascher B; Rzany B; Kestemont P; Hilton S; Heckmann M; Bodokh I; Noah EM; Boineau D; Kerscher M; Volteau M; Le Berre P; Picaut P
    Aesthet Surg J; 2020 Jan; 40(1):93-104. PubMed ID: 30893430
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-term Efficacy and Safety of Liquid AbobotulinumtoxinA Formulation for Moderate-to-Severe Glabellar Lines: A Phase III, Double-Blind, Randomized, Placebo-Controlled and Open-Label Study.
    Kestemont P; Hilton S; Andriopoulos B; Prygova I; Thompson C; Volteau M; Ascher B
    Aesthet Surg J; 2022 Feb; 42(3):301-313. PubMed ID: 34472596
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Subject satisfaction and psychological well-being with escalating abobotulinumtoxinA injection dose for the treatment of moderate to severe glabellar lines.
    Dayan S; Joseph J; Moradi A; Lorenc ZP; Coleman K; Ablon G; Kaufman-Janette J; Cox SE; Campbell A; Munavalli G; Prygova I
    J Cosmet Dermatol; 2022 Jun; 21(6):2407-2416. PubMed ID: 35266281
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and Safety of Botulinum Toxin Type A for Treatment of Glabellar Lines: A Network Meta-Analysis of Randomized Controlled Trials.
    Li X; Sui C; Xia X; Chen X
    Aesthetic Plast Surg; 2023 Feb; 47(1):365-377. PubMed ID: 36097079
    [TBL] [Abstract][Full Text] [Related]  

  • 9. An analysis of safety data from five phase III clinical trials on the use of botulinum neurotoxin type A-ABO for the treatment of glabellar lines.
    Rubin M; Dover J; Maas C; Nestor M
    Aesthet Surg J; 2009 Nov; 29(6 Suppl):S50-6. PubMed ID: 19945005
    [TBL] [Abstract][Full Text] [Related]  

  • 10. AbobotulinumtoxinA for the Treatment of Moderate-to-Severe Glabellar Lines: A Randomized, Dose-Escalating, Double-Blind Study.
    Joseph J; Moradi A; Lorenc ZP; Coleman K; Ablon G; Kaufman-Janette J; Cox SE; Campbell A; Dayan S; Berg AK; Munavalli G
    J Drugs Dermatol; 2021 Sep; 20(9):980-987. PubMed ID: 34491016
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy, Safety, and Subject Satisfaction After AbobotulinumtoxinA Treatment for Moderate to Severe Glabellar Lines.
    Monheit GD; Baumann L; Maas C; Rand R; Down R
    Dermatol Surg; 2020 Jan; 46(1):61-69. PubMed ID: 31356432
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of the safety and efficacy of a biosimilar abobotulinum toxin type A in treating moderate-to-severe glabellar lines: A non-inferiority double blinded randomized controlled trial.
    Afshani SM; Samadi A; Ayatollahi A; Kashani MN; Ahmad Nasdrollahi S; Hosseini H; Rezagholi Z; Hedayatjoo B; Hazegh Fetratjoo D; Ghobadi MA; Anari A; Saeedifar S; Firooz A
    J Cosmet Dermatol; 2022 Jun; 21(6):2398-2406. PubMed ID: 35340107
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The efficacy and safety of liquid-type botulinum toxin type A for the management of moderate to severe glabellar frown lines.
    Kim JE; Song EJ; Choi GS; Lew BL; Sim WY; Kang H
    Plast Reconstr Surg; 2015 Mar; 135(3):732-741. PubMed ID: 25719692
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Does Increasing the Dose of Abobotulinumtoxina Impact the Duration of Effectiveness for the Treatment of Moderate to Severe Glabellar Lines?
    Joseph JH; Eaton LL; Robinson J; Pontius A; Williams EF
    J Drugs Dermatol; 2016 Dec; 15(12):1544-1549. PubMed ID: 29106437
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Significantly Increased Patient Satisfaction Following Liquid Formulation AbobotulinumtoxinA Treatment in Glabellar Lines: FACE-Q Outcomes From a Phase 3 Clinical Trial.
    Ascher B; Rzany B; Kestemont P; Hilton S; Heckmann M; Bodokh I; Noah EM; Boineau D; Kerscher M; Volteau M; Le Berre P; Picaut P
    Aesthet Surg J; 2020 Aug; 40(9):1000-1008. PubMed ID: 31550352
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Botulinum toxin type A for facial wrinkles.
    Camargo CP; Xia J; Costa CS; Gemperli R; Tatini MD; Bulsara MK; Riera R
    Cochrane Database Syst Rev; 2021 Jul; 7(7):CD011301. PubMed ID: 34224576
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Time to onset of response of abobotulinumtoxina in the treatment of glabellar lines: a subset analysis of phase 3 clinical trials of a new botulinum toxin type A.
    Schlessinger J; Monheit G; Kane MA; Mendelsohn N
    Dermatol Surg; 2011 Oct; 37(10):1434-42. PubMed ID: 21745254
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and Safety of Botulinum Toxin Type A in the Treatment of Glabellar Lines: A Meta-Analysis of Randomized, Placebo-Controlled, Double-Blind Trials.
    Guo Y; Lu Y; Liu T; Zhou Y; Yang P; Zhu J; Chen L; Yang Q
    Plast Reconstr Surg; 2015 Sep; 136(3):310e-318e. PubMed ID: 26313835
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A Phase III Clinical Study of the Efficacy and Safety of Botulinum Toxin Type A (MASPORT) with DYSPORT for the Treatment of Glabellar Lines.
    Hedayat K; Ehsani AH
    Aesthetic Plast Surg; 2024 Feb; 48(3):324-332. PubMed ID: 38233684
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A randomized, placebo-controlled, double-blind phase III trial investigating the efficacy and safety of incobotulinumtoxinA in the treatment of glabellar frown lines using a stringent composite endpoint.
    Hanke CW; Narins RS; Brandt F; Cohen JL; Donofrio LM; Downie J; Heinz M; Harrington L; McDaniel DH; Nestor M; Schlessinger J; Schlöbe A; Taub A; Weiss RA
    Dermatol Surg; 2013 Jun; 39(6):891-9. PubMed ID: 23506308
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.